purpos
current
food
drug
administr
fda
approv
antibodi
immunoglobulin
gs
igg
howev
infect
initi
mucos
surfac
iga
primari
immun
effector
antibodi
immunoglobulin
mani
properti
make
attract
therapeut
agent
mucos
surfac
iga
polymer
make
effici
agglutin
antigen
igg
therebi
facilit
immun
exclus
iga
antiinflammatori
due
inabl
activ
complement
abil
inhibit
complement
activ
igg
igm
griffiss
goroff
russel
et
al
associ
secretori
compon
sc
iga
resist
proteolysi
igg
chintalacharuvu
morrison
lindh
studi
anim
human
suggest
passiv
administr
iga
could
provid
protect
wide
rang
pathogen
includ
bacteria
toxin
virus
hiv
respiratori
syncyti
viru
rsv
gupta
et
al
hem
et
al
kozlowski
neutra
recombin
secretori
iga
siga
streptococcu
mutan
approv
europ
topic
administr
prevent
dental
cari
et
al
antitransferrin
iga
shown
effect
cancer
administ
intraven
brook
et
al
howev
topic
administr
antirsv
iga
show
signific
efficaci
prophylact
agent
clinic
trial
although
igg
antirsv
shown
effect
administ
intramuscularli
approv
fda
use
human
subramanian
et
al
thu
although
much
potenti
igabas
therapeut
prophylact
agent
essenti
use
recombin
antibodi
technolog
defin
correl
iga
structur
function
studi
biolog
iga
determin
mechan
iga
siga
provid
protect
knowledg
facilit
design
product
effect
igabas
immunotherapeut
wide
rang
applic
product
recombin
iga
pose
mani
challeng
iga
exist
two
differ
isotyp
one
isotyp
three
differ
allotyp
form
decis
must
made
iga
form
appropri
intend
applic
like
igg
product
iga
requir
express
heavi
light
chain
howev
make
polymer
iga
piga
third
chain
jchain
must
also
express
siga
need
fourth
polypeptid
sc
must
also
express
chain
must
appropri
assembl
secret
iga
glycoprotein
two
five
nlink
glycan
present
heavi
chain
olink
glycan
present
hing
region
nlink
glycan
present
expos
surfac
molecul
mattu
et
al
merri
et
al
jchain
sc
also
glycoprotein
glycan
iga
play
import
role
function
particular
attent
must
paid
structur
glycan
attach
differ
express
system
cost
product
also
import
consider
thu
identif
appropri
express
system
signific
challeng
produc
recombin
iga
recombin
iga
produc
sever
differ
express
system
includ
insect
plant
mammalian
cell
transgen
anim
system
advantag
limit
potenti
applic
larg
quantiti
protein
produc
insect
cell
agricultur
amount
plant
make
express
system
econom
altern
produc
therapeut
diagnost
reagent
normal
posttransl
modif
signal
peptid
cleavag
intrachain
interchain
disulfid
bond
format
addit
olink
nlink
carbohydr
observ
plant
insect
cell
howev
nglycan
attach
insect
plant
cell
differ
normal
found
human
iga
butter
et
al
jarvi
finn
martin
et
al
ogonah
et
al
nglycan
present
iga
produc
transgen
anim
depend
speci
use
differ
glycosyl
might
influenc
vivo
biolog
properti
biodistribut
halflif
effector
function
intact
fulli
assembl
iga
produc
mammalian
cell
howev
case
cost
import
consider
regardless
express
system
use
care
character
vivo
biolog
properti
result
iga
essenti
antibodi
produc
insect
cell
howev
insect
cell
appear
contain
enzym
requir
produc
sialyl
complex
carbohydr
jarvi
finn
although
express
glycosyltransferas
lead
protein
mammalianlik
glycan
jarvi
finn
insect
cell
also
produc
protein
glycan
core
fucosyl
oligomannos
found
mammalian
cell
ogonah
et
al
recombin
produc
spodoptera
frugiperada
insect
cell
doubl
infect
baculoviru
contain
chimer
mousehuman
hchain
lchain
yield
cell
per
h
obtain
secret
antibodi
h
l
heterodim
contain
olink
galnac
disaccharid
nlink
high
mannos
glycan
bound
antigen
pazophenylarson
promyelocyt
leukemia
cell
complement
compon
iga
dimer
assembl
ineffici
human
jchain
also
express
major
extracellular
iga
monom
associ
jchain
carayannopoulo
et
al
clear
instabl
coval
bond
iga
jchain
due
differ
carbohydr
structur
product
level
jchain
baculoviru
system
contrast
found
iga
produc
chines
hamster
ovari
cho
cell
mattu
et
al
insectcellproduc
lack
nlink
carbohydr
c
h
bind
cell
express
human
sc
also
produc
cell
yield
mgl
although
recombin
sc
fulli
glycosyl
shown
associ
mous
dimer
iga
rindisbach
et
al
transgen
tobacco
maiz
soybean
alfalfa
expect
yield
kg
therapeut
antibodi
per
acr
cost
onetenth
would
requir
product
antibodi
use
mammalian
cell
although
plant
produc
protein
high
mannos
complex
nlink
glycan
attach
link
xylos
link
core
fucos
instead
link
core
fucos
found
mammal
addit
plant
normal
add
gal
complex
nglycan
lack
galactosyltransferas
addit
sialic
acid
also
absent
although
gal
ad
complex
carbohydr
mous
human
galactosyltransferas
express
tobacco
plant
xylosyl
fucosyl
affect
age
leaf
antibodi
purifi
also
affect
structur
nglycan
even
kdel
endoplasm
reticulum
anchorag
domain
ad
mous
igg
nglycan
contain
xylos
fucos
present
ramirez
et
al
signific
concern
whether
glycan
attach
plant
immunogen
although
ige
specif
plant
glycoallergen
xylos
fucos
detect
serum
allerg
patient
van
ree
et
al
two
six
mice
immun
subcutan
mous
produc
tobacco
plant
detect
immun
respons
howev
note
assay
use
detect
isotyp
includ
ige
chargelegu
et
al
immunoglobulin
specif
streptococcu
mutan
sobrinu
antigen
iii
cell
surfac
adhes
molecul
produc
tobacco
plant
et
al
hybrid
igaproduc
plant
gener
cross
plant
express
murinehuman
hchain
murin
lchain
dimer
iga
produc
subsequ
cross
plant
express
murin
jchain
final
cross
rabbit
scproduc
plant
result
express
siga
singl
plant
cell
howev
iga
coval
associ
sc
addit
sc
bound
iga
kda
smaller
expect
size
kda
antibodi
yield
mg
antibodykg
fresh
plant
materi
obtain
et
al
transgen
anim
attract
express
system
largescal
product
antibodi
howev
mammal
differ
sialic
acid
structur
abil
add
bisect
glcnac
gal
core
fucosyl
make
choic
speci
import
consider
raju
et
al
transgen
mice
secret
chimer
murineporcin
iga
transmiss
gastroenter
coronaviru
tgev
engin
sola
et
al
regulatori
sequenc
use
target
iga
synthesi
mammari
gland
concentr
porcin
iga
milk
mgml
detect
level
serum
transgen
anim
transgen
mice
overexpress
murin
pigr
mammari
gland
epitheli
cell
shown
increas
level
iga
milk
compar
control
mice
de
groot
et
al
mous
iga
phosphorylcholin
express
transgen
mice
pig
sheep
lo
et
al
mammalian
express
system
use
extens
product
iga
siga
date
nonimmunoglobulin
produc
murin
myeloma
cho
cell
line
express
system
choic
howev
glycan
attach
express
system
ident
present
normal
human
iga
addit
observ
incomplet
assembl
produc
cho
cell
chintalacharuvu
et
al
unpublish
data
murin
carbohydr
differ
present
human
protein
produc
murin
myeloma
lack
bisect
glcnac
link
trimannosyl
core
nlink
glycan
fukuta
et
al
implic
import
antibodi
function
davi
et
al
life
et
al
umana
et
al
addit
sialic
acid
structur
vari
among
mammalian
speci
human
cell
attach
nacetylneuramin
acid
nana
wherea
mous
cell
attach
nglycolylneuramin
acid
ngna
raju
et
al
mous
cell
also
synthes
signific
amount
circul
igg
human
epitop
abund
glycoprotein
nonprim
mammal
prosimian
new
world
monkey
absent
old
world
monkey
ape
man
galili
presenc
carbohydr
structur
therapeut
protein
would
signific
consequ
presenc
epitop
recombin
antibodi
quit
variabl
human
produc
cell
contain
residu
hill
et
al
hchain
glycan
produc
possess
epitop
lund
et
al
lund
et
al
howev
much
nlink
glycan
human
produc
murin
myeloma
cell
appear
contain
morrison
et
al
unpublish
observ
expos
natur
glycan
iga
might
facilit
process
glycan
form
chines
hamster
ovari
cell
appear
lack
glycosyltransferas
necessari
gener
bisect
glcnac
link
sialic
acid
nlink
glycan
routier
et
al
transfect
exogen
glycosyltransferas
cho
cell
made
possibl
express
protein
contain
human
glycan
less
glycan
heterogen
lee
et
al
weikert
et
al
vitro
galactosyl
sialyl
also
use
glycoengin
antibodi
molecul
raju
et
al
addit
cho
cell
engin
overexpress
protein
disulfid
isomeras
facilit
assembl
recombin
protein
davi
et
al
gener
strategi
design
immunoglobulin
express
vector
cassett
facilit
manipul
antibodi
gene
vector
express
hand
lchain
usual
contain
differ
select
marker
although
bicistron
express
vector
contain
human
land
jchain
gene
human
murin
dihydrofol
reductas
dhfr
gene
also
describ
wolbank
et
al
amount
lchain
produc
transfect
appear
limit
amount
antibodi
produc
effect
method
gener
transfect
first
isol
good
lchainproduc
transfect
second
round
transfect
hchain
select
use
differ
marker
yield
transfect
produc
larg
amount
antibodi
chintalacharuvu
et
al
chintalacharuvu
morrison
morton
et
al
altern
cotransfect
land
hchain
perform
one
marker
usual
use
select
berdoz
et
al
variabl
constant
region
gene
initi
obtain
genom
clone
routin
amplifi
polymeras
chain
reaction
pcr
cdna
made
antibodyproduc
cell
berdoz
et
al
campbel
et
al
coloma
et
al
gavilondocowley
et
al
gilli
et
al
larrick
et
al
orlandi
et
al
pcr
use
success
rapid
clone
modif
v
region
antibodi
mani
differ
specif
sequenc
variabl
region
clone
known
specif
pcr
primer
produc
sequenc
unknown
degener
primer
set
anneal
rel
conserv
leader
first
framework
sequenc
end
use
limit
number
primer
amplifi
heavychain
isotyp
two
isotyp
light
chain
includ
appropri
restrict
site
primer
straightforward
clone
pcr
product
express
vector
addit
fulli
human
iga
also
produc
clone
v
region
singlechain
fv
fragment
select
phage
display
berdoz
corthesi
boel
et
al
hul
et
al
sc
produc
proteolyt
cleavag
pigr
epitheli
transcytosi
see
chapter
initi
siga
produc
cocultur
igaproduc
hybridoma
madindarbi
canin
kidney
mdck
cell
express
pigr
hirt
et
al
anoth
approach
polymer
murin
iga
produc
mice
ascit
inject
lewi
rat
associ
rat
pigr
siga
rat
sc
collect
bile
renegar
et
al
altern
approach
sc
produc
introduc
stop
codon
posit
correspond
natur
cleavag
site
pigr
rindisbach
et
al
purifi
piga
hybridoma
cell
line
combin
purifi
recombin
sc
test
tube
crottet
et
al
lullau
et
al
rindisbach
et
al
siga
complex
affin
antigen
nativ
molecul
form
correct
coval
bond
two
molecul
lullau
et
al
although
siga
normal
product
two
differ
cell
type
recombin
siga
produc
singl
cell
gene
human
sc
transfect
myeloma
cell
produc
chimer
mousehuman
piga
contain
endogen
murin
jchain
siga
produc
virtual
sc
coval
bound
dimer
iga
siga
assembl
appear
take
place
golgi
apparatu
chintalacharuvu
morrison
subsequ
cho
berdoz
et
al
johansen
et
al
babi
hamster
kidney
bhk
vidarsson
et
al
cell
use
produc
siga
transfect
gene
human
jchain
sc
cell
alreadi
express
chimer
iga
control
element
use
direct
iga
express
depend
cell
type
transfect
blineag
cell
line
express
recombin
hand
lchain
gene
usual
driven
immunoglobulin
promot
enhanc
element
bruggemann
et
al
chintalacharuvu
et
al
chintalacharuvu
morrison
knight
et
al
express
iga
blineag
cell
line
advantag
endogen
jchain
incorpor
recombin
iga
strong
heterolog
promot
human
cytomegaloviru
cmv
promot
also
use
direct
iga
express
viral
control
element
led
high
antibodi
yield
advantag
versatil
function
varieti
cell
type
cho
bhk
co
cell
well
lymphoid
cell
chimer
murinehuman
produc
cell
line
berdoz
et
al
berdoz
corthesi
chintalacharuvu
et
al
chintalacharuvu
morrison
morton
et
al
trill
et
al
vidarsson
et
al
chimer
murineporcin
iga
sola
et
al
isotyp
chimer
murinerabbit
iga
schneiderman
et
al
produc
cell
also
produc
plasmacytoma
cell
braathen
et
al
bruggemann
et
al
chimer
murinebovin
iga
produc
murin
hybridoma
knight
et
al
vaccinia
viru
express
system
advantag
extend
host
rang
viru
make
possibl
express
heterolog
gene
almost
mammalian
cell
type
viral
promotor
vaccinia
late
promot
flank
vaccinia
thymidin
kinas
sequenc
direct
recombin
viral
genom
viral
mammalian
transcript
translat
element
use
regul
express
case
human
sc
equival
amount
protein
mgl
produc
human
sc
vaccinia
regulatori
sequenc
use
hela
human
epitheli
monkey
fibroblast
tk
human
fibroblast
cell
line
rindisbach
et
al
recombin
sc
produc
capabl
associ
dimer
mous
iga
contain
complex
nglycan
celllinespecif
process
rabbit
sc
murin
sc
also
produc
use
vaccinia
viru
express
system
nonigproduc
hybridoma
cell
line
crottet
et
al
glycosyl
profil
recombin
murin
sc
found
sc
murin
milk
bile
varieti
method
use
purifi
recombin
iga
siga
purif
protocol
base
select
antigen
wide
use
addit
synthet
peptid
residu
deriv
streptococc
protein
shown
bind
human
iga
peptid
design
sap
streptococc
igabind
peptid
shown
deplet
iga
human
serum
siga
saliva
sap
appear
bind
similar
affin
sandin
et
al
make
attract
reagent
isol
purif
recombin
human
iga
lectin
concavalin
use
purifi
sc
rindisbach
et
al
lectin
jacalin
bind
olink
glycan
hing
tag
also
ad
aid
purif
recombin
protein
separ
protein
proteas
cleavag
site
tag
remov
follow
protein
purif
tag
cterminu
human
sc
alter
secret
either
baculoviru
vaccinia
viru
express
system
rindisbach
et
al
flag
tag
use
purifi
murin
sc
crottet
et
al
recombin
technolog
made
possibl
shed
light
requir
necessari
iga
assembl
secret
polym
format
associ
protein
jchain
pigrsc
studi
use
sitedirect
mutagenesi
domainexchang
protein
identifi
structur
element
import
assembl
iga
siga
hchain
lchain
synthes
polysom
transloc
lumen
endoplasm
reticulum
assembl
monom
higher
polym
hand
lchain
first
associ
noncoval
coval
disulfid
bond
predomin
coval
assembl
pathway
human
n
molecul
hl
intermedi
hand
lchain
first
disulfid
bond
form
coval
associ
h
l
monom
contrast
major
intermedi
assembl
h
major
molecul
lack
disulfid
bond
hand
lchain
chintalacharuvu
morrison
c
h
absent
particip
disulfid
bond
format
lchain
chintalacharuvu
morrison
lchain
coval
associ
hing
proxim
c
h
structur
c
h
influenc
effici
disulfid
bond
format
chintalacharuvu
et
al
immunoglobulin
possess
extens
cterminu
call
tailpiec
particip
polymer
igm
also
form
polym
also
possess
tailpiec
tailpiec
contain
nlink
carbohydr
addit
site
requir
iga
dimer
format
atkin
et
al
conserv
penultim
cy
residu
involv
polymer
studi
use
domainexchang
protein
reveal
addit
tailpiec
structur
motif
c
h
critic
polym
assembl
jchain
incorpor
assembl
dimer
contain
jchain
requir
c
tailpiec
effici
dimer
assembl
presenc
c
braathen
et
al
chintalacharuvu
et
al
yoo
et
al
polym
contain
jchain
bind
pigr
brandtzaeg
prydz
see
chapter
coval
noncoval
interact
found
piga
pigr
human
pigr
form
disulfid
bond
human
rat
rabbit
dimer
iga
tamer
et
al
rabbit
igaf
isotyp
shown
bind
rabbit
pigr
coval
wherea
rabbit
igag
isotyp
noncoval
associ
schneiderman
et
al
disulfid
bond
format
appear
facilit
transport
rather
might
import
stabil
pigasc
complex
although
jchain
promot
iga
polym
assembl
human
produc
cho
cell
abl
form
dimer
absenc
morton
et
al
jchain
contain
eight
cy
residu
two
form
disulfid
bond
six
form
intrachain
disulfid
bridg
cterminu
jchain
well
two
three
intrachain
disulfid
bridg
found
dispens
format
iga
polym
requir
bind
sc
johansen
et
al
either
jchain
requir
iga
polymer
polym
stabil
noncoval
interact
although
noncoval
associ
polym
bound
free
sc
transcytosi
pigrexpress
mdck
cell
greatli
diminish
johansen
et
al
jchain
requir
pigr
bind
c
tailpiec
requir
jchain
incorpor
surpris
studi
use
domainexchang
protein
show
c
requir
bind
transport
pigrexpress
mdck
cell
braathen
et
al
hexham
et
al
expos
loop
c
domain
contain
amino
acid
qepsqgttt
predict
bind
site
pigr
hexham
et
al
amino
acid
also
particip
pigr
bind
white
capra
howev
natur
occur
mutant
lack
amino
acid
c
includ
amino
acid
found
associ
rat
sc
transport
blood
bile
manner
indistinguish
piga
switzer
et
al
nevertheless
green
fluoresc
protein
gfp
fusion
protein
contain
monomer
dimer
form
amino
acid
peptid
phage
display
librari
resembl
amino
acid
transport
pigr
hexham
et
al
suggest
peptid
might
use
target
deliv
therapeut
mucos
site
although
addit
c
result
protein
incorpor
jchain
bound
pigr
hybrid
molecul
transport
pigrexpress
mdck
cell
low
effici
chintalacharuvu
et
al
environ
mucos
surfac
hostil
one
ph
gastrointestin
tract
rang
stomach
intestin
lumen
iga
evolv
function
hostil
environ
addit
c
result
protein
stabl
wildtyp
ph
replac
c
c
increas
stabil
hybrid
antibodi
especi
low
ph
chintalacharuvu
et
al
sc
serv
increas
stabil
iga
see
chapter
mice
clear
less
readili
dimer
iga
chintalacharuvu
morrison
siga
resist
degrad
dimer
iga
expos
intestin
wash
berdoz
et
al
chintalacharuvu
morrison
crottet
corthesi
addit
recombin
siga
produc
plant
found
stabl
human
oral
caviti
igg
contain
ident
v
region
et
al
mani
bacteria
caus
diseas
mucos
surfac
secret
proteas
cleav
type
proteas
cleav
proser
residu
wherea
type
cleav
prothr
residu
streptococc
speci
produc
type
metalloproteas
wherea
neisseria
meningitid
n
gonorrhoea
haemophilu
influenza
produc
type
type
proteas
olink
glycan
hing
appear
import
sensit
streptococc
proteas
batten
et
al
length
hing
shown
import
recognit
cleavag
proteas
senior
woof
see
chapter
studi
use
human
hing
mutant
reveal
bacteri
proteas
requir
specif
amino
acid
sequenc
cleavag
batten
et
al
mani
proteas
abl
cleav
hybrid
shorten
hing
senior
et
al
proteas
abl
cleav
altern
peptid
bond
wildtyp
site
present
senior
woof
addit
sequenc
requir
hing
c
h
c
h
requir
cleavag
proteas
h
influenza
n
gonorrhoea
chintalacharuvu
et
al
immunoglobulin
amedi
immun
effector
mechan
phagocytosi
antibodydepend
cellmedi
cytotox
adcc
respiratori
burst
cytokin
releas
mediat
igaspecif
receptor
present
human
macrophag
monocyt
eosinophil
neutrophil
monteiro
et
al
see
chapter
compar
receptor
express
mous
monomer
dimer
iga
bind
activ
immun
effector
cell
vidarsson
et
al
iga
form
complex
receptor
bind
c
h
h
interfac
herr
et
al
initi
studi
use
recombin
human
domainexchang
protein
reveal
c
c
necessari
suffici
bind
carayannopoulo
et
al
specif
residu
c
h
loop
c
h
loop
import
bind
signal
receptor
carayannopoulo
et
al
pleass
et
al
electrostat
interact
acid
residu
seem
play
major
role
bind
mutat
residu
littl
affect
affin
receptor
pleass
et
al
crystal
structur
complex
fc
iga
confirm
extend
conclus
herr
et
al
interfac
compos
central
hydrophob
core
compos
aliphat
portion
side
chain
flank
charg
residu
nglycan
approach
within
directli
contact
receptor
bound
upright
orient
cterminu
would
orient
near
cell
membran
bound
cellassoci
bound
sc
would
appear
occlud
bind
site
siga
enhanc
stimul
phagocytosi
vidarsson
et
al
inde
activ
neutrophil
effector
function
prevent
siga
motegi
kita
wherea
iga
fix
complement
via
classic
pathway
debat
whether
activ
altern
pathway
might
depend
speci
produc
iga
see
chapter
chimer
murinehuman
pseudomona
aeruginosa
lipopolysaccharid
lp
mediat
deposit
onto
surfac
purifi
lp
whole
bacteria
preston
et
al
although
chimer
mousehuman
specif
hapten
dansyl
bound
appear
activ
altern
pathway
subsequ
step
complement
cascad
factor
b
cleavag
termin
complex
bind
observ
chuang
morrison
howev
human
serum
iga
shown
activ
altern
pathway
enhanc
kill
bacteria
circumst
janoff
et
al
recombin
rabbit
iga
isotyp
activ
altern
pathway
schneiderman
et
al
absenc
glycosyl
iga
result
reduct
bind
zhang
lachmann
immunoglobulin
siga
heavili
glycosyl
protein
oligosaccharid
side
chain
account
molecular
mass
iga
h
chain
tomana
et
al
jchain
baenzig
royl
et
al
sc
hugh
et
al
phalipon
et
al
presenc
absenc
glycan
well
structur
affect
iga
assembl
secret
function
delet
nlink
glycan
c
h
tailpiec
affect
assembl
secret
human
chuang
morrison
inhibit
secret
murin
iga
taylor
wall
absenc
nlink
carbohydr
human
affect
bind
pigr
chuang
morrison
iga
produc
insect
cell
glycosyl
c
h
found
critic
interact
carayannopoulo
et
al
howev
case
iga
produc
cho
cell
mattu
et
al
possibl
reflect
structur
differ
occur
alter
structur
either
nlink
carbohydr
olink
glycan
hing
nandor
olink
oligosaccharid
iga
sc
propos
function
ligand
bacteri
adhes
appear
import
provid
protect
serv
receptor
analogu
innat
immun
dalla
rolf
manti
et
al
royl
et
al
see
chapter
addit
nlink
glycan
recombin
human
sc
shown
critic
direct
appropri
local
iga
confer
protect
shigella
flexneri
infect
mice
phalipon
et
al
secret
recombin
human
sc
requir
glycosyl
cell
grown
presenc
tunicamycin
inhibit
nlink
glycosyl
unabl
secret
recombin
human
sc
cottet
corthesi
carbohydr
structur
also
influenc
pharmacokinet
properti
glycoprotein
asialoglycoproteinreceptor
asgpr
mediat
rapid
clearanc
glycoprotein
bear
termin
nacetylgalactosamin
galnac
gal
mice
three
allotyp
rapidli
clear
serum
asgpr
express
liver
wherea
much
less
clear
circul
rout
rifai
et
al
found
highli
sialyl
mattu
et
al
increas
amount
sialic
acid
content
carbohydr
found
decreas
interact
asgpr
basset
et
al
greater
serum
level
might
explain
part
rapid
clearanc
asgpr
grow
public
health
concern
increas
presenc
antibioticresist
diseasecaus
microb
increas
number
bacteria
led
renew
interest
use
passiv
antibodi
treatment
infecti
diseas
passiv
antibodi
wide
use
preantibiot
era
abandon
widespread
use
antibiot
becam
common
review
casadeval
et
al
current
antibodi
use
clinic
trail
system
administr
howev
possibl
greatest
use
antibodi
might
lie
administr
prevent
treatment
infect
mucos
surfac
major
portal
entri
infecti
agent
public
health
perspect
prevent
import
direct
applic
antibodi
site
infect
block
pathogen
entri
local
administr
antibodi
provid
effect
concentr
drug
immedi
topic
applic
easi
attract
mode
administr
therapeut
base
iga
would
appear
hold
great
promis
rout
treatment
siga
confer
protect
administ
passiv
breast
milk
addit
recombin
iga
use
varieti
diseas
model
recombin
iga
specif
wide
rang
bacteri
product
produc
fulli
human
dimer
piga
siga
produc
cho
cell
bind
helicobact
pylori
ureas
berdoz
corthesi
chimer
murinehuman
recogn
pseudomona
aeruginosa
serogroup
lipopolysaccharid
preston
et
al
recombin
igg
porin
neisseria
meningitidi
produc
bhk
cell
vidarsson
et
al
mixtur
monomer
dimer
contain
jchain
shown
trigger
respiratori
burst
polymorphonuclear
leukocyt
pmn
monomer
iga
siga
shown
activ
phagocytosi
heatkil
neisseria
polymer
chimer
specif
enterotoxin
clostridium
difficil
show
increas
avid
enhanc
efficaci
durat
protect
human
colon
epitheli
cell
monolay
destruct
effect
toxin
comparison
igg
monomer
iga
contain
v
region
stubb
et
al
protect
shigella
flexneri
infect
confer
iga
specif
serotyp
lp
shown
enhanc
piga
associ
sc
sc
effect
local
iga
epitheli
surfac
nasal
caviti
bronchial
mucu
wherea
iga
distribut
diffus
tissu
phalipon
et
al
first
human
trial
monoclon
secretori
antibodi
perform
use
tobacco
plantderiv
siga
streptococcu
mutan
et
al
sigaigg
hybrid
antibodi
found
stabl
murin
igg
human
oral
caviti
siga
shown
prevent
oral
colon
mutan
least
month
human
immunodefici
viru
hiv
resist
women
express
iga
genit
tract
oppos
infect
women
kaul
et
al
see
chapter
iga
appear
play
import
role
prevent
sexual
transmiss
iga
persist
seroneg
individu
neutral
also
prevent
transcytosi
across
tight
epitheli
cell
layer
devito
et
al
devito
et
al
human
nonimmunodomin
epitop
produc
cho
cell
shown
neutral
transepitheli
entri
vitro
use
polar
epitheli
monolay
although
appear
less
effect
igg
igm
viru
neutral
complement
protect
human
peripher
blood
mononuclear
cell
pbmc
hiv
primari
isol
wolbank
et
al
transmiss
gastroenter
coronaviru
tgev
infect
enter
respiratori
tissu
caus
close
mortal
newborn
pig
recombin
chimer
murineporcin
iga
produc
cell
neutral
tgev
effici
presum
due
increas
avid
dimer
iga
transgen
mice
express
porcin
iga
mammari
gland
shown
secret
viru
neutral
antibodi
milk
suggest
transgen
technolog
use
prevent
neonat
infect
diseas
livestock
sola
et
al
recombin
iga
also
show
promis
treatment
parasit
diseas
malaria
therapeut
base
iga
mighti
advantag
igg
parasit
initi
hypergammaglobulinemia
smokescreen
evad
immun
system
miller
et
al
igg
also
bind
inhibitori
receptor
therebi
interf
immun
respons
parasit
clyne
et
al
pleass
et
al
produc
recombin
murinehuman
chimer
merozoit
surfac
protein
antigen
plasmodium
yoelii
effect
stimul
oxid
burst
human
neutrophil
vitro
howev
murin
model
malaria
provid
protect
lethal
parasit
infect
mous
contain
ident
v
region
presum
human
fail
interact
mous
fc
receptor
human
express
monocyt
neutrophil
potent
effector
cell
merozoit
kill
well
kupffer
dendrit
cell
involv
antigen
present
stimul
human
monocyt
inhibit
tumor
necrosi
factor
tnf
interleukin
il
synthesi
elev
shown
correl
poor
prognosi
malaria
addit
high
titer
plasmodiumspecif
iga
serum
biswa
et
al
breast
milk
leke
et
al
found
human
live
endem
area
suggest
iga
play
crucial
role
immun
malaria
recombin
iga
might
effect
therapeut
agent
malaria
chimer
murinehuman
major
ragwe
pollen
antigen
sun
et
al
shown
prevent
increas
airway
hyperrespons
lung
eosinophilia
sensit
mice
schwarz
et
al
studi
suggest
siga
also
serv
mucos
vaccin
deliveri
system
eightaminoacid
sequenc
loop
connect
e
f
domain
rabbit
pigrsc
residu
replac
nineaminoacid
linear
epitop
flexneri
invasin
b
engin
antigen
sc
although
mutat
result
significantli
lower
rate
secret
express
mdck
cell
fail
transport
dimer
iga
mutat
sc
abl
associ
murin
dimer
iga
antigen
siga
togeth
cholera
toxin
adjuv
oral
administ
mice
abl
elicit
product
invasin
band
rabbit
scspecif
antibodi
addit
h
pylori
groe
chaperonin
fuse
cterminu
human
sc
serv
mucos
vaccin
carrier
antigen
sc
shown
associ
polymer
dimer
iga
isol
murin
hybridoma
favr
et
al
recombin
iga
shown
promis
anticanc
therapeut
recombin
human
produc
bhk
cell
specif
epcam
tumorassoci
antigen
shown
mediat
kill
tumor
cell
unstimul
pmn
also
mediat
phagocytosi
tumor
cell
macrophag
although
effici
human
contain
v
region
hul
et
al
addit
chimer
murinehuman
hla
class
ii
molecul
express
bcell
lymphoma
effect
direct
kill
varieti
target
cell
line
pmn
target
cell
lysi
inhibit
indic
receptor
respons
antitumor
activ
dechant
et
al
neutrophil
exert
potent
cytolyt
capac
varieti
tumor
cell
presenc
antitumor
antibodi
immatur
neutrophil
mobil
bone
marrow
granulocyt
colonystimul
factor
treatment
shown
effici
trigger
tumor
cell
lysi
via
otten
et
al
carcinoembryon
antigen
cea
express
apic
side
carcinoma
cell
buchegg
et
al
burtin
et
al
thought
much
radiolabel
anticea
igg
antibodi
use
detect
baum
et
al
therapi
colon
carcinoma
breitz
et
al
unabl
reach
due
particular
histolog
local
chimer
cea
transcytos
pigr
might
effect
agent
terskikh
et
al
novel
mousehuman
chimer
dimer
iga
specif
human
transferrin
receptor
htfr
shown
inhibit
prolifer
induc
apoptosi
myeloma
cell
line
chintalacharuvu
et
al
unpublish
result
prost
et
al
shinohara
et
al
immunoglobulin
mediat
immun
protect
mucos
surfac
major
portal
entri
mani
pathogen
therefor
hold
great
potenti
therapeut
prophylat
agent
one
challeng
produc
therapeut
iga
ensur
complex
recombin
protein
desir
function
properti
advanc
molecular
biolog
techniqu
allow
rapid
clone
express
character
antibodi
result
greater
understand
protein
assembl
secret
pathway
ligandreceptor
interact
role
carbohydr
glycoprotein
function
antibodi
effector
function
challeng
use
result
inform
produc
effect
igabas
therapeut
molecul
posttransl
modif
import
correct
antibodi
function
import
posttransl
modif
glycosyl
consist
correct
glycosyl
especi
import
produc
function
iga
siga
hchain
jchain
sc
signific
amount
surfaceexpos
carbohydr
murin
myeloma
cho
cell
express
system
choic
product
antibodi
howev
express
system
add
carbohydr
ident
found
human
iga
use
human
cell
line
express
might
help
resolv
problem
transgen
anim
attract
express
system
especi
product
siga
milk
houdebin
howev
choic
speci
becom
import
speciesspecif
differ
glycan
addit
howev
differ
might
less
issu
recombin
protein
use
topic
administr
recombin
antibodi
industri
infanc
show
great
promis
rapid
extens
growth
expect
iga
take
place
alongsid
igg
import
therapeut
molecul
howev
take
place
certain
issu
problem
must
address
includ
issu
cost
complex
biolog
requir
use
expens
media
along
high
cost
associ
purif
process
avail
cost
bovin
serum
mani
growth
media
issu
address
use
serumfre
growth
media
batchtobatch
variat
heterogen
final
product
also
import
consider
stoll
et
al
design
novel
bioreactor
configur
largescal
cultur
suspens
mckinney
et
al
sauer
et
al
care
monitor
control
cultur
condit
monica
et
al
nyberg
et
al
schneider
et
al
engin
product
cell
line
improv
glycosyl
assembl
might
solv
problem
davi
et
al
weikert
et
al
recombin
iga
shown
effect
pathogen
bacteria
virus
addit
iga
might
also
protect
cancer
cell
although
mice
express
homologu
use
human
transgen
mice
van
egmond
et
al
might
facilit
studi
role
iga
immun
protect
variou
diseas
model
iga
import
mucos
secret
sc
import
role
anchor
siga
mucu
howev
clinic
trial
done
use
oral
nasal
administr
piga
lack
sc
zeitlin
et
al
thing
consid
expect
recombin
iga
siga
assum
ever
increas
role
clinic
